Geldhof A, Slater J, Clark M, Chandran U, Coppola D. Exposure to infliximab during pregnancy: post-marketing experience. Drug Saf 2020;43:febrero. [Ref.ID 103539]

Dommasch ED, Kim SC, Lee MP, Gagne JJ. Risk of serious infection in patients receiving systemic medications for the treatment of psoriasis. JAMA Dermatol 2019:10 de mayo. [Ref.ID 103131]

Anónimo. Baricitinib et polyarthrite rhumatoïde. Prescrire 2018;38:171-2. [Ref.ID 102586]

Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018;555:29 de marzo. [Ref.ID 102577]

Montané E, Arellano AL, Sanz Y, Roca J, Farré M. Drug-related deaths in hospital inpatients: a retrospective cohort study. Br J Clin Pharmacol 2017;84:1. [Ref.ID 102184]

Ruggiero A, Ferrara P, Attinà G, Rizzo D, Riccardi C. Renal toxicity and chemotherapy in children with cancer. Br J Clin Pharmacol 2017;83:2605-14. [Ref.ID 102170]

Alijotas-Reig J, Esteve-Valverde E. Embarazo y enfermedades autoinmunitarias. Med Clin (Barc) 2017;148:161-3. [Ref.ID 101400]

Anónimo. Encéphalopathies postérieures réversibles d'origine médicamenteuse. Prescrire 2016;36:907-10. [Ref.ID 101007]

Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet 2016;388:2023-38. [Ref.ID 100911]

Anónimo. Ustékinumab et psoriasis chez les adolescents. Prescrire 2016;36:733-4. [Ref.ID 100889]

Anónimo. Sécukinumab et rumatisme psoriasique. Prescrire 2016;36:732. [Ref.ID 100888]

Anónimo. Sécukinumab et psoriasis en plaques. Prescrire 2016;36:727-31. [Ref.ID 100887]

Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R. Tratamiento de las gestantes con enfermedades reumáticas o autoinmunitarias sistémicas con fármacos inmunodepresores y biológicos. Med Clin (Barc) 2016;147:352-60. [Ref.ID 100793]

Bijlsma JW, Welsing PMJ, Woodworth TG, Middelink LM, Pethö-Schramm A, Bernasconi C, Borm ME, Wortel CH, ter Borg EJ, Jahangier ZN, van der Laan W, Bruyn GAW, Baudoin P, Wijngaarden S, Vos PAJM, Bos R, Starmans MFJ, Griep EN, Griep-Wentink JRM, Allaart CF, Heurkens AHM, Teitsma XM, Tekstra J, Marijnissen ACA, Lafeber FPJ, Jacobs JWG. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. N Engl J Med 2016;388:343-55. [Ref.ID 100644]

Scott DL. Beyond methotrexate monotherapy for early rheumatoid arthritis. N Engl J Med 2016;388:309-10. [Ref.ID 100642]

Anónimo. Aprémilast. Prescrire 2016;35:90-4. [Ref.ID 100523]

Hazlewood GS, Barnabe C, Tomlinson G, Marshall D, Devoe D, Bombardier C. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis. BMJ 2016;352:i1777. [Ref.ID 100196]

Anónimo. Tocilizumab en ajout au méthotrexate d'emblée dans les polyarthrites rhumatoïdes agressives. Prescrire 2015;35:740. [Ref.ID 99847]

Anónimo. Hypertension artérielle essentielle chez un adulte: premiers traitements. Prescrire 2015;35:683-6. [Ref.ID 99722]

Hesdorffer CS, Longo DL. Drug-induced megaloblastic anemia. N Engl J Med 2015;373:1649-58. [Ref.ID 99629]